Novo Nordisk's drugs are being linked to an eye condition that can cause vision loss, while health tech companies made CNBC's ...

Researchers have identified the brain cells responsible for the weight-loss effects of semaglutide without triggering its undesirable side effects. This discovery paves the way for more targeted ...

A popular weight-loss drug may be changing how doctors treat obesity—but scientists are just starting to uncover exactly how ...

In a 36-week study, semaglutide was found to aid in weight loss for people with schizophrenia without worsening psychotic ...

A study, which was published in The New England Journal of Medicine, found that tirzepatide (Zepbound) is more effective for ...

Treatment should be stopped if nonarteritic anterior ischemic optic neuropathy, which can cause vision loss, is diagnosed.

Researchers have zeroed in on yet another possible ocular concern for diabetes patients who take popular GLP-1 therapies in a ...

Novo Nordisk — maker of Ozempic and Wegovy — confirmed that hair loss is an identified risk for semaglutide and is listed as a side effect in the product information. “Future studies are ...

The European Medicines Agency’s (EMA) safety committee, PRAC, said Friday that it has concluded that Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), a rare eye condition that can lead to ...

Semaglutide is a long-acting GLP-1 receptor ... outcome was explored in analyses of subgroups defined according to information obtained at baseline (age, sex, race, ethnic group, region, body ...

Using semaglutide injections, scientists were able to reverse life-threatening cases of liver disease in a new clinical trial published in The New England Journal of Medicine. Semaglutide ...

Relatedly, we did not collect semaglutide dosage information over the study period, in part because dosing can change frequently. Generalizability may be limited to individuals not using Medicaid ...